The presented device provides a platform that can be used to closely monitor any pharmaceutical modifications to the synaptic transmission process by PD treatments, Alzheimer’s disease treatments, alpha-synuclein deposits, depression therapies, and other therapies for neurodegenerative disorders, at the single-vesicle level. Here, SNCA is linked to Parkinson disease.